Concord Biotech quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	309	247	+25.1%
EBITDA	104	88.5	+18.0%
EBITDA margin	33.8%	35.8%	−2.0 pts
Profit before tax	96.1	83.4	+15.3%
Net profit	69.6	63.1	+10.3%
EPS	₹6.65	₹6.03	+10.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023

Expenses
	309	257	326	278	247	204	430	244	310	216	319	241
	10.2	12.8	15.3	10.0	13.4	13.7	9.4	14.7	10.0	10.3	10.8	8.2
	319	270	341	288	260	218	439	259	320	226	330	249
	63.7	69.9	70.5	66.6	57.3	59.9	80.3	61.0	68.1	55.0	55.7	47.4
	16.2	11.3	15.7	20.4	13.6	12.8	10.3	12.2	21.7	11.8	11.5	23.2
	−6.3	−26.9	−0.4	−21.3	−21.9	−27.7	37.9	−20.7	−13.4	−18.5	21.7	−23.5
	52.3	43.6	47.8	46.8	44.5	37.9	39.0	34.6	33.7	31.7	34.0	30.7
	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.5	0.5
	18.4	18.1	19.5	18.7	18.4	17.8	14.6	13.3	13.3	13.2	13.7	13.5
	78.8	77.2	74.0	66.3	65.1	59.6	72.0	59.2	63.5	54.6	61.9	57.1
	223	193	227	198	177	160	254	160	187	148	199	149
	104	82.4	119	99.0	88.5	61.4	190	98.0	137	81.3	134	106
	86.0	64.3	99.0	80.2	70.1	43.6	176	84.7	123	68.1	121	92.4
Profit
	96.1	77.1	114	90.1	83.4	57.2	185	99.3	133	78.2	131	100
	0.0	0.0	0.0	−3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	96.1	77.1	114	86.9	83.4	57.2	185	99.3	133	78.2	131	100
	25.0	20.4	28.6	21.6	22.0	14.1	41.8	23.7	34.1	19.4	30.0	25.8
	0.9	0.3	−3.0	0.9	0.6	0.6	1.3	1.5	0.5	0.5	3.7	−0.3
	25.9	20.6	25.6	22.5	22.6	14.7	43.2	25.2	34.6	19.9	33.7	25.5
	−0.7	1.3	−0.2	−0.7	2.3	1.5	−1.6	1.8	−3.0	1.4	−2.2	3.0
	69.6	57.7	88.5	63.6	63.1	44.1	140	75.9	95.7	59.6	95.0	77.6
	70.2	56.4	88.6	64.3	60.8	42.6	142	74.1	98.7	58.2	97.2	74.6
	−8.6	17.1	13.3	22.9	21.9	−2.8	7.5	−1.5	−0.2	0.2	0.4	−0.6
	61.0	74.8	102	86.6	84.9	41.2	148	74.5	95.5	59.8	95.4	76.9
	70.7	58.5	88.8	64.5	63.6	44.1	140	75.9	95.7	59.6	95.0	77.6
	−1.1	−0.8	−0.3	−0.8	−0.5	0.0	0.0	0.0	0.0	0.0	—	0.0
Per share
	₹6.65	₹5.52	₹8.46	₹6.08	₹6.03	₹4.21	₹13.42	₹7.26	₹9.15	₹5.70	₹9.08	₹7.41
	₹6.65	₹5.52	₹8.46	₹6.08	₹6.03	₹4.21	₹13.42	₹7.26	₹9.15	₹5.70	₹9.08	₹7.41
Other comprehensive income — detail
	−8.6	17.1	13.3	22.9	21.9	−2.8	7.5	—	—	—	—	—
	−8.4	17.1	13.6	23.1	21.9	−2.8	7.5	−1.5	−0.2	0.2	0.4	−0.6
	0.0	0.0	0.4	0.0	0.0	0.0	0.0	—	—	—	—	—
	−0.2	0.0	0.0	−0.1	−0.1	—	—	—	—	—	—	—
	62.1	75.6	102	87.5	85.4	41.2	148	74.5	95.5	59.8	95.4	76.9
	−1.1	−0.8	−0.4	−0.9	−0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹6.65	₹5.52	₹8.46	₹6.08	₹6.03	₹4.21	₹13.42	₹7.26	₹9.15	₹5.70	₹9.08	₹7.41
	₹6.65	₹5.52	₹8.46	₹6.08	₹6.03	₹4.21	₹13.42	₹7.26	₹9.15	₹5.70	₹9.08	₹7.41
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	236	203	240	212	198	159	301	192	234	168	230	194
	76.2%	78.9%	73.7%	76.3%	80.2%	77.9%	70.1%	78.5%	75.4%	77.6%	72.1%	80.4%
Adjusted (ex-exceptional items) — derived
	96.1	77.1	114	90.1	83.4	57.2	185	99.3	133	78.2	131	100
	0.0	0.0	0.0	−3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	69.6	57.7	88.5	66.1	63.1	44.1	140	75.9	95.7	59.6	95.0	77.6
	₹6.65	₹5.52	₹8.46	₹6.31	₹6.03	₹4.21	₹13.42	₹7.26	₹9.15	₹5.70	₹9.08	₹7.41

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CONCORDBIO₹1,225.00

Concord Biotech Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersBIOCON DIVISLAB CAPLIPOINT EMCURE BLUEJET ERIS GRANULES ACUTAASMcap ₹12,815 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	240.8	319.0	215.8	310.2	244.2	429.9	204.0	247.1	277.8	326.1	257.5	309.1
Other Income	8.2	10.8	10.3	10.0	14.7	9.4	13.7	13.4	10.0	15.3	12.8	10.2
Total Income	249.0	329.8	226.1	320.2	258.9	439.3	217.7	260.4	287.7	341.4	270.3	319.2
Expenses
+ Cost of Materials Consumed	47.4	55.7	55.0	68.1	61.0	80.3	59.9	57.3	66.6	70.5	69.9	63.7
+ Purchases of Stock-in-Trade	23.2	11.5	11.8	21.7	12.2	10.3	12.8	13.6	20.4	15.7	11.3	16.2
+ Changes in Inventories	-23.5	21.7	-18.5	-13.4	-20.7	37.9	-27.7	-21.9	-21.3	-0.4	-26.9	-6.3
+ Employee Benefit Expense	30.7	34.0	31.7	33.7	34.6	39.0	37.9	44.5	46.8	47.8	43.6	52.3
+ Finance Costs	0.5	0.5	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0
+ Depreciation & Amortisation	13.5	13.7	13.2	13.3	13.3	14.6	17.8	18.4	18.7	19.5	18.1	18.4
+ Other Expenses	57.1	61.9	54.6	63.5	59.2	72.0	59.6	65.1	66.3	74.0	77.2	78.8
Total Expenses	148.9	198.9	147.9	186.9	159.6	254.2	160.4	177.0	197.6	227.2	193.2	223.1
EBITDA	105.9	134.3	81.3	136.7	98.0	190.4	61.4	88.5	99.0	118.5	82.4	104.4
EBIT	92.4	120.6	68.1	123.4	84.7	175.8	43.6	70.1	80.2	99.0	64.3	86.0
Profit
PBT before Exceptional Items	100.1	130.9	78.2	133.3	99.3	185.1	57.2	83.4	90.1	114.3	77.1	96.1
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3	0.0	0.0	0.0
Pretax Income	100.1	130.9	78.2	133.3	99.3	185.1	57.2	83.4	86.9	114.3	77.1	96.1
+ Current Tax	25.8	30.0	19.4	34.1	23.7	41.8	14.1	22.0	21.6	28.6	20.4	25.0
+ Deferred Tax	-0.3	3.7	0.5	0.5	1.5	1.3	0.6	0.6	0.9	-3.0	0.3	0.9
Tax Expense	25.5	33.7	19.9	34.6	25.2	43.2	14.7	22.6	22.5	25.6	20.6	25.9
+ Share of Associates & JVs	3.0	-2.2	1.4	-3.0	1.8	-1.6	1.5	2.3	-0.7	-0.2	1.3	-0.7
Net Income	77.6	95.0	59.6	95.7	75.9	140.4	44.1	63.1	63.6	88.5	57.7	69.6
+ Net Income — Continuing Ops	74.6	97.2	58.2	98.7	74.1	141.9	42.6	60.8	64.3	88.6	56.4	70.2
+ Other Comprehensive Income	-0.6	0.4	0.2	-0.2	-1.5	7.5	-2.8	21.9	22.9	13.3	17.1	-8.6
Total Comprehensive Income	76.9	95.4	59.8	95.5	74.5	147.9	41.2	84.9	86.6	101.7	74.8	61.0
Net Income to Common	77.6	95.0	59.6	95.7	75.9	140.4	44.1	63.6	64.5	88.8	58.5	70.7
Minority Interest	0.0	—	0.0	0.0	0.0	0.0	0.0	-0.5	-0.8	-0.3	-0.8	-1.1
Per Share
Basic EPS	7.41	9.08	5.70	9.15	7.26	13.42	4.21	6.03	6.08	8.46	5.52	6.65
Diluted EPS	7.41	9.08	5.70	9.15	7.26	13.42	4.21	6.03	6.08	8.46	5.52	6.65
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	7.5	-2.8	21.9	22.9	13.3	17.1	-8.6
+ Items NOT to be Reclassified to P&L	-0.6	0.4	0.2	-0.2	-1.5	7.5	-2.8	21.9	23.1	13.6	17.1	-8.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.0	0.0	0.0	0.0	0.4	0.0	0.0
+ Items to be Reclassified to P&L	—	—	—	—	—	—	—	-0.1	-0.1	0.0	0.0	-0.2
Comprehensive Income — Owners of Parent	76.9	95.4	59.8	95.5	74.5	147.9	41.2	85.4	87.5	102.1	75.6	62.1
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.5	-0.9	-0.4	-0.8	-1.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	7.41	9.08	5.70	9.15	7.26	13.42	4.21	6.03	6.08	8.46	5.52	6.65
Diluted EPS — Continuing Operations	7.41	9.08	5.70	9.15	7.26	13.42	4.21	6.03	6.08	8.46	5.52	6.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	193.7	230.1	167.5	233.9	191.8	301.4	158.9	198.0	212.0	240.3	203.2	235.5
Gross Margin %	80.45	72.15	77.62	75.40	78.54	70.11	77.89	80.16	76.33	73.68	78.92	76.20
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	100.1	130.9	78.2	133.3	99.3	185.1	57.2	83.4	90.1	114.3	77.1	96.1
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3	0.0	0.0	0.0
Net Income Adj (tax-effected)	77.6	95.0	59.6	95.7	75.9	140.4	44.1	63.1	66.1	88.5	57.7	69.6
EPS Adj	7.41	9.08	5.70	9.15	7.26	13.42	4.21	6.03	6.31	8.46	5.52	6.65
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Concord Biotech Q2 FY27 results (July–September 2026)

Filed with NSE on Tuesday, 27 October 2026 at 7:08 pm IST

Concord Biotech (NSE: CONCORDBIO) reported its Q2 FY27 results (July–September 2026) on Tuesday, 27 October 2026 at 7:08 pm IST. Consolidated net profit attributable to shareholders was ₹70.7 crore, up 11.1% from ₹63.6 crore in Q2 FY26 and up 20.7% from ₹58.5 crore in Q1 FY27. Revenue from operations was ₹309 crore, up 25.1% year on year and up 20.0% from the previous quarter.

Q2 FY26 results (a year earlier): 13 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹70.7 Cr+11.1% vs Q2 FY26+20.7% vs Q1 FY27Total incl. minority interest ₹69.6 Cr
Revenue from operations: ₹309 Cr+25.1% vs Q2 FY26+20.0% vs Q1 FY27
Operating margin (EBIT): 27.8%−0.5 pts vs Q2 FY26+2.9 pts vs Q1 FY27EBIT ₹86 Cr
EBITDA: ₹104 Cr+18.0% vs Q2 FY26+26.7% vs Q1 FY27margin 33.8%
Earnings per share (basic): ₹6.65+10.3% vs Q2 FY26+20.5% vs Q1 FY27
Net profit margin: 22.9%−2.9 pts vs Q2 FY26+0.1 pts vs Q1 FY27

Questions

What was Concord Biotech's net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹70.7 crore, up 11.1% from ₹63.6 crore in Q2 FY26 and up 20.7% from ₹58.5 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹69.6 crore.

How were Concord Biotech's Q2 FY27 results?

Both grew from a year earlier: net profit was up 11.1% at ₹70.7 crore and revenue was up 25.1% at ₹309 crore. The operating margin was 27.8%, down 0.5 percentage points from 28.4% a year earlier. Against Q1 FY27, net profit was up 20.7% and revenue up 20.0%.

What was Concord Biotech's net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹129 crore, up 20.0% from ₹108 crore in the same months a year earlier. Revenue from operations was ₹567 crore, up 25.6%.

What was Concord Biotech's revenue in Q2 FY27?

Revenue from operations was ₹309 crore, up 25.1% year on year and up 20.0% from the previous quarter.

What was Concord Biotech's EPS in Q2 FY27?

Basic earnings per share were ₹6.65, against ₹6.03 in Q2 FY26.

What was Concord Biotech's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹261 crore in FY26 (April 2025–March 2026), down 29.8% from ₹372 crore in FY25. It was ₹308 crore in FY24.

What was Concord Biotech's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹86 crore, a margin of 27.8%, against 25.0% in Q1 FY27 and 28.4% in Q2 FY26. EBITDA was ₹104 crore, 33.8% of revenue.

What is Concord Biotech's net profit margin?

Concord Biotech's net profit margin was 22.9% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 25.7% in Q2 FY26 (down 2.9 percentage points). For FY26 as a whole it was 24.7%.

When did Concord Biotech announce its Q2 FY27 results?

On Tuesday, 27 October 2026 at 7:08 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 13 November 2025.

How has Concord Biotech's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹64.5 crore in Q3 FY26, ₹88.8 crore in Q4 FY26, ₹58.5 crore in Q1 FY27 and ₹70.7 crore in Q2 FY27. That is ₹282 crore over the four quarters, down 12.8% from ₹324 crore in the four quarters before. Revenue from operations: ₹278 crore, ₹326 crore, ₹257 crore and ₹309 crore.

What was Concord Biotech's revenue in FY26?

Revenue from operations was ₹1,055 crore in FY26 (April 2025–March 2026), down 12.1% from ₹1,200 crore in FY25. It was ₹1,017 crore in FY24.

When will Concord Biotech announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Concord Biotech figures come from?

From Concord Biotech's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 27 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.